Sage Therapeutics (SAGE) News Today $8.28 -0.38 (-4.39%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$8.28 +0.01 (+0.06%) As of 03/28/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Fox Run Management L.L.C. Acquires 32,579 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)Fox Run Management L.L.C. increased its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 199.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 48,950 shares of the biopharmaceutical company's stockMarch 29 at 4:20 AM | marketbeat.comScotiabank Reaffirms Their Buy Rating on Tempest Therapeutics (TPST)March 29 at 1:45 AM | markets.businessinsider.comSage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Rating of "Hold" by AnalystsSage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) has received a consensus rating of "Hold" from the nineteen analysts that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, fifteen have assigned a hold recommendationMarch 28 at 2:40 AM | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) Shares Bought by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. raised its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 157.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 169,057 shares of the biopharmMarch 21, 2025 | marketbeat.comSage Therapeutics (SAGE) Up 7.4% Since Last Earnings Report: Can It Continue?March 13, 2025 | msn.comSage Therapeutics (NASDAQ:SAGE) Earns Underperform Rating from Analysts at Bank of AmericaBank of America began coverage on shares of Sage Therapeutics in a research report on Tuesday. They issued an "underperform" rating and a $5.00 price target on the stock.March 12, 2025 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Stock Price Crosses Above Fifty Day Moving Average - What's Next?Sage Therapeutics (NASDAQ:SAGE) Stock Price Crosses Above 50 Day Moving Average - Time to Sell?March 11, 2025 | marketbeat.comSage Therapeutics resumed with an Underperform at BofAMarch 10, 2025 | markets.businessinsider.comAttention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Playstudios, Inc. (NASDAQ: MYPS); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf as Certain Class Actions Move ForwardMarch 10, 2025 | financialpost.comAttention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Playstudios, Inc. (NASDAQ: MYPS); and Sage Therapeutics, Inc. (NASDAQ: SAGE): GraMarch 10, 2025 | investing.comGrabar Law Office Investigates Claims on Behalf of Shareholders of Sage Therapeutics, Inc. (SAGE)March 8, 2025 | investing.comSage’s medical chief is latest leader to leave biotechMarch 5, 2025 | bizjournals.comSigns of hiring at Boston-area life sciences companiesMarch 5, 2025 | bizjournals.comSage Therapeutics Chief Medical Officer to step downMarch 4, 2025 | markets.businessinsider.comSage Therapeutics Announces R&D Leadership TransitionMarch 4, 2025 | businesswire.comSage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Recommendation of "Hold" from AnalystsShares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) have earned a consensus recommendation of "Hold" from the nineteen ratings firms that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, fifteen have assignedMarch 3, 2025 | marketbeat.comSage Therapeutics, Inc. (SAGE): Among the Best Psychedelic Stocks to Buy in 2025March 1, 2025 | msn.comJanux Therapeutics Inc (JANX) Gets a Hold from ScotiabankFebruary 28, 2025 | markets.businessinsider.comNewAmsterdam Pharma Company (NAMS) Gets a Buy from ScotiabankFebruary 27, 2025 | markets.businessinsider.comIs Sage Therapeutics, Inc. (SAGE) the Best Small-Cap Growth Stock to Buy Now?February 26, 2025 | insidermonkey.comSage Therapeutics price target established at JPMorganFebruary 25, 2025 | markets.businessinsider.comHC Wainwright Issues Optimistic Outlook for SAGE EarningsSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Equities researchers at HC Wainwright boosted their Q1 2025 earnings per share estimates for shares of Sage Therapeutics in a research note issued to investors on Wednesday, February 12th. HC Wainwright analyst D. Tsao now expects that the bioFebruary 17, 2025 | marketbeat.comShort Interest in Sage Therapeutics, Inc. (NASDAQ:SAGE) Decreases By 32.0%Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) was the recipient of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 4,170,000 shares, a decline of 32.0% from the January 15th total of 6,130,000 shares. Approximately 7.8% of the company's shares are short sold. Based on an average daily volume of 1,710,000 shares, the days-to-cover ratio is currently 2.4 days.February 15, 2025 | marketbeat.comEquities Analysts Set Expectations for SAGE Q3 EarningsSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for shares of Sage Therapeutics in a research note issued to investors on Tuesday, February 11th. Leerink Partnrs analyst M. Goodman anticipates that the biopharmaceutical companyFebruary 15, 2025 | marketbeat.comSAGE Therapeutics Faces Legal Challenges: Potential Impact on Financial Stability and GrowthFebruary 13, 2025 | msn.comSage Therapeutics price target lowered to $12 from $14 at ScotiabankFebruary 13, 2025 | finance.yahoo.comBrokers Offer Predictions for SAGE Q1 EarningsSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Leerink Partnrs issued their Q1 2025 earnings per share estimates for Sage Therapeutics in a research note issued on Tuesday, February 11th. Leerink Partnrs analyst M. Goodman expects that the biopharmaceutical company will earn ($1.03) per shFebruary 13, 2025 | marketbeat.comSage stock price target cut to $12 by H.C. WainwrightFebruary 12, 2025 | msn.comQ4 2024 SAGE Therapeutics Inc Earnings CallFebruary 12, 2025 | uk.finance.yahoo.comA Glimpse Into The Expert Outlook On Sage Therapeutics Through 7 AnalystsFebruary 12, 2025 | benzinga.comCanaccord cuts Sage Therapeutics price target to $8, holds ratingFebruary 12, 2025 | msn.comSage Therapeutics (NASDAQ:SAGE) Price Target Lowered to $12.00 at ScotiabankScotiabank reduced their price target on shares of Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating on the stock in a research report on Wednesday.February 12, 2025 | marketbeat.comWedbush Reaffirms Neutral Rating for Sage Therapeutics (NASDAQ:SAGE)Wedbush reissued a "neutral" rating and set a $6.00 target price on shares of Sage Therapeutics in a report on Wednesday.February 12, 2025 | marketbeat.comCanaccord Genuity Group Cuts Sage Therapeutics (NASDAQ:SAGE) Price Target to $8.00Canaccord Genuity Group reduced their price target on Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating for the company in a report on Wednesday.February 12, 2025 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Receives Hold Rating from Needham & Company LLCNeedham & Company LLC restated a "hold" rating on shares of Sage Therapeutics in a research note on Wednesday.February 12, 2025 | marketbeat.comSage Therapeutics' (SAGE) "Neutral" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "neutral" rating and issued a $12.00 price target (down from $14.00) on shares of Sage Therapeutics in a report on Wednesday.February 12, 2025 | marketbeat.comSage brushes off 'strategic alternatives' questions during earnings callFebruary 12, 2025 | bizjournals.comSage Therapeutics, Inc. (SAGE) Q4 2024 Earnings Call TranscriptFebruary 11, 2025 | seekingalpha.comSage Therapeutics, Inc. 2024 Q4 - Results - Earnings Call PresentationFebruary 11, 2025 | seekingalpha.comSage Therapeutics (NASDAQ:SAGE) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPSSage Therapeutics (NASDAQ:SAGE - Get Free Report) posted its earnings results on Tuesday. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%.February 11, 2025 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Announces Earnings Results, Misses Estimates By $0.02 EPSSage Therapeutics (NASDAQ:SAGE - Get Free Report) posted its earnings results on Tuesday. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%.February 11, 2025 | marketbeat.comSage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business UpdatesFebruary 11, 2025 | businesswire.comSage Therapeutics (SAGE) Projected to Post Quarterly Earnings on TuesdaySage Therapeutics (NASDAQ:SAGE) will be releasing earnings after the market closes on Tuesday, February 11, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=660037)February 9, 2025 | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) Given Average Recommendation of "Hold" by BrokeragesShares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) have been assigned a consensus rating of "Hold" from the twenty ratings firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, sixteen have issued a hold recommFebruary 6, 2025 | marketbeat.comSage Therapeutics (SAGE) Projected to Post Earnings on TuesdaySage Therapeutics (NASDAQ:SAGE) will be releasing earnings after the market closes on Tuesday, February 11, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=660037)February 4, 2025 | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) Sees Significant Increase in Short InterestSage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) was the target of a significant growth in short interest in January. As of January 15th, there was short interest totalling 6,130,000 shares, a growth of 26.9% from the December 31st total of 4,830,000 shares. Approximately 11.7% of the shares of the stock are sold short. Based on an average daily volume of 1,590,000 shares, the short-interest ratio is currently 3.9 days.February 3, 2025 | marketbeat.comFY2025 Earnings Estimate for SAGE Issued By Leerink PartnrsSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Research analysts at Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for Sage Therapeutics in a research note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the biophJanuary 31, 2025 | marketbeat.comThe Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero TherapeuticsJanuary 30, 2025 | finance.yahoo.comSAGE Therapeutics (SAGE) Gets a Hold from Mizuho SecuritiesJanuary 30, 2025 | markets.businessinsider.comSage Therapeutics price target raised to $9 from $6 at MizuhoJanuary 30, 2025 | markets.businessinsider.com Remove Ads Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address SAGE Media Mentions By Week SAGE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SAGE News Sentiment▼0.780.81▲Average Medical News Sentiment SAGE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SAGE Articles This Week▼49▲SAGE Articles Average Week Remove Ads Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Tarsus Pharmaceuticals News Today Harmony Biosciences News Today Travere Therapeutics News Today Janux Therapeutics News Today Disc Medicine News Today Agios Pharmaceuticals News Today Apogee Therapeutics News Today Mesoblast News Today Vera Therapeutics News Today Galapagos News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SAGE) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | SponsoredTrump… a socialist? Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy sage Stock Free sage Stock Alerts